Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up

C. Mathers, John; Elliott, Faye; Macrae, Finlay; Mecklin, Jukka‐Pekka; Möslein, Gabriela; E. McRonald, Fiona; Bertario, Lucio; Gareth Evans, D.; Gerdes, Anne‐Marie; Ho, Judy; Lindblom, Annika; J. Morrison, Patrick; Rashbass, Jem; Ramesar, Raj; T. Seppälä, Toni; Thomas, Huw; Sheth, Harsh; Pylvänäinen, Kirsi; Reed, Lynn; M. Borthwick, Gillian; Timothy Bishop, D.; Burn, John; behalf of the CAPP2 Investigators, on

doi:10.1158/1940-6207.capr-22-0044

Public

Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up

Published in Cancer Prevention Research • Jul 25, 2022

Authors:

John C. Mathers

Faye Elliott

Finlay Macrae

Abstract

ABSTRACT: The CAPP2 trial investigated the long-term effects of aspirin and resistant starch on cancer incidence in patients with Lynch syndrome (LS). Participants with LS were randomized double-blind to 30 g resistant starch (RS) daily or placebo for up to 4 years. We present long-term cancer outco...

Subject

Medicine

Colorectal cancer

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!